Oral absorption of the HIV protease inhibitors: A current update

Advanced Drug Delivery Reviews

Volumn 39, Issue 1-3, 1999, Pages 211-238

  Williams, Gregory C ^a   Sinko, Patrick J ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

CYP3A4; Efflux; Induction; Inhibition; Metabolism; P glycoprotein; Pharmacokinetics

Indexed keywords

ABSORPTION; DRUG INTERACTIONS; ENZYME INHIBITION; METABOLISM; PHARMACOKINETICS; PROTEINS; SOLUBILITY; VIRUSES;

HUMAN IMMUNODEFICIENCY VIRUS (HIV);

CONTROLLED DRUG DELIVERY;

AMPRENAVIR; AMPRENAVIR MESYLATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; GLYCOPROTEIN P; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG METABOLISM; DRUG PENETRATION; DRUG TRANSPORT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE ABSORPTION; INTESTINE SECRETION; LIVER; NONHUMAN; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW;

EID: 0032847425     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(99)00027-7     Document Type: Article

References (119)

1. Kakuda T.N., Struble K.A., Piscitelli S.C. Protease inhibitors for the treatment of human immunodeficiency virus infection. Am. J. Health Syst. Pharm. 55:1998;233-254.
2. Flexner C. HIV-protease inhibitors. N. Engl. J. Med. 338:1998;1281-1292.
3. Carpenter C.C., Fischl M.A., Hammer S.M., Hirsch M.S., Jacobsen D.M., Katzenstein D.A., Montaner J.S., Richman D.D., Saag M.S., Schooley R.T., Thompson M.A., Vella S., Yeni P.G., Volberding P.A. Antiretroviral therapy for HIV infection in 1998. Updated recommendations of the international AIDS Society - USA panel. J.Am. Med. Assoc. 280:1998;78-86.
4. Moyle G.J., Gazzard B.G., Cooper D.A., Gatell J. Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use. Drugs. 55:1998;383-404.
5. Perry C.M., Noble S. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection. Drugs. 55:1998;461-486.
6. Pettit S.C., Michael S.F., Swanstrom R. The specificity of the HIV-1 protease. Perspect. Drug Discovery Des. 1:1993;69-83.
7. March D.R., Fairlie D.P. Designing New Antiviral Drugs For AIDS: HIV-1 Protease and Its Inhibitors. 1996;R.G. Landes, Austin, TX.
8. Lin J.H. Human immunodeficiency virus protease inhibitors. From drug design to clinical studies. Adv. Drug Del. Rev. 27:1997;215-233.
9. Beach J.W. Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions. Clin. Ther. 20:1998;2-25.
10. 12th ed Budavari S., O'Neil M.J., Smith A., Heckelman P.E., Kinneary J.F. The Merck Index. 1996;Merck, Whitehouse Station, NJ.
11. ®. Medical Economics Data Production Co., Montvale, NJ, 1998, pp. 1625-1628.
12. ®. Medical Economics Data Production Co., Montvale, NJ, 1998, p. 476-480.
13. ®. Medical Economics Data Production Co., Montvale, NJ, 1998, pp. 459-464.
14. Longer M., Shetty B., Zamansky I., Tyle P. Preformulation studies of a novel HIV protease inhibitor, AG1343. J. Pharm. Sci. 84:1995;1090-1093.
15. Kim E.E., Baker C.T., Dwyer M.D., Murcko M.A., Rao B.G., Tung R.D., Navia M.A. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc. 117:1995;1181-1182.
16. Kempf D.J., Marsh K.C., Denissen J.F., McDonald E., Vasavanonda S., Flentge C.A., Green B.E., Fino L., Park C.H., Kong X.P., Wideburg N.E., Saldivar A., Ruiz L., Kati W.M., Sham H.L., Robins T., Stewart K.D., Hsu A., Plattner J.J., Leonard J.M., Norbeck D.W. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA. 92:1995;2484-2488.
17. Kempf D.J., Sham H.L., Marsh K.C., Flentge C.A., Betebenner D., Green B.E., McDonald E., Vasavanonda S., Saldivar A., Wideburg N.E., Kati W.M., Ruiz L., Zhao C., Fino L., Patterson J., Molla A., Plattner J.J., Norbeck D.W. Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. J. Med. Chem. 41:1998;602-617.
18. Dorsey B.D., Levin R.B., McDaniel S.L., Vacca J.P., Guare J.P., Darke P.L., Zugay J., Emini E.A., Schleif W.A., Quintero J.C., Lin J.H., Chen I.-W., Holloway M.K., Fitzgerald P.M., Axel M.G., Ostovic D., Anderson P.S., Huff J.R. L-735,524: The design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 37:1994;3443-3451.
19. Kaldor S.W., Kalish V.J., Davies J.F., Shetty B.V., Fritz J.E., Appelt K., Burgess J.A., Campanale K.M., Chirgadze N.Y., Clawson D.K., Dressman B.A., Hatch S.D., Khalil D.A., Kosa M.B., Lubbehusen P.P., Muesing M.A., Patick A.K., Reich S.H., Su K.S., Tatlock J.H. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 40:1997;3979-3985.
20. Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., Chaisson R.E., Quinn T.C., Chadwick K., Margolick J., Brookmeyer R., Gallant J., Markowitz M., Ho D.D., Richman D.D., Siliciano R.F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 278:1997;1295-1300.
21. 1 acid glycoprotein. J. Infect. Dis. 171:1995;546-551.
22. 1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors. J. Infect. Dis. 175:1997;1063-1070.
23. West M., Fairlie D.P. Targeting HIV-1 protease: a test of drug-design methodologies. Trends Pharmacol. Sci. 16:1995;67-75.
24. Sudoh M., Pauletti G.M., Yao W., Moser W., Yokoyama A., Pasternak A., Sprengeler P.A., Smith A.B., Hirschmann R., Borchardt R.T. Transport characteristics of peptidomimetics. Effect of the pyrrolinone bioisostere on transport across Caco-2 cell monolayers. Pharm. Res. 15:1998;719-725.
25. Alsenz J., Steffen H., Alex R. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers [Erratum: Alsenz, J., Steffen, H. and Alex, R. (1998) Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm. Res. 15, 958]. Pharm. Res. 15:1998;423-428.
26. ®. American Society of Health-System Pharmacists, Bethesda, MD, 1998, pp. 572-580.
27. ®. Medical Economics Data Production Co., Montvale, NJ, 1998, pp. 2471-2475.
28. Lin J.H., Chen I.-W., Vastag K.J., Ostovic D. pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab. Dispos. 23:1995;730-735.
29. Yeh K.C., Deutsch P.J., Haddix H., Hesney M., Hoagland V., Ju W.D., Justice S.J., Osborne B., Sterrett A.T., Stone J.A., Woolf E., Waldman S. Single-dose pharmacokinetics of indinavir and the effect of food [published erratum appears in (1998) Antimicrob. Agents Chemother. 42, 1308]. Antimicrob. Agents Chemother. 42:1998;332-338.
30. Chen I.-W., Vastag K.J., Lin J.H. High-performance liquid chromatographic determination of a potent and selective HIV protease inhibitor (L-735,524) in rat, dog and monkey plasma. J. Chromatogr. B. Biomed. Sci. Appl. 672:1995;111-117.
31. Kwei G.Y., Novak L.B., Hettrick L.A., Reiss E.R., Ostovic D., Loper A.E., Lui C.Y., Higgins R.J., Chen I.-W., Lin J.H. Regiospecific intestinal absorption of the HIV protease inhibitor L-735,524 in beagle dogs. Pharm. Res. 12:1995;884-888.
32. Hunter J., Hirst B.H. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral absorption. Adv. Drug Del. Rev. 25:1997;129-157.
33. Markowitz M., Conant M., Hurley A., Schluger R., Duran M., Peterkin J., Chapman S., Patick A., Hendricks A., Yuen G.J., Hoskins W., Clendeninn N., Ho D.D. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J. Infect. Dis. 177:1998;1533-1540.
34. Noble S., Faulds D. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs. 52:1996;93-112.
35. Danner S.A., Carr A., Leonard J.M., Lehman L.M., Gudiol F., Gonzales J., Raventos A., Rubio R., Bouza E., Pintado V., Aguado A.G., De Lomas J.G., Delgado R., Borleffs J.C., Hsu A., Valdes J.M., Boucher C.A., Cooper D.A. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333:1995;1528-1533.
36. Press Release from Vertex Pharmaceuticals. December (1995) Glaxo Wellcome begins phase I/II clinical trials with Vertex Pharmaceuticals' protease inhibitor for HIV. Vertex Pharmaceuticals, Cambridge, MA.
37. Williams P.E., Muirhead G.J., Madigan M.J., Mitchell A.M., Shaw T. Disposition and bioavailability of the HIV-proteinase inhibitor, Ro 31-8959, after single doses in healthy volunteers. Br. J. Clin. Pharmacol. 34:1992;155P-156P.
38. St. Clair M.H., Millard J., Rooney J., Tisdale M., Parry N., Sadler B.M., Blum M.R., Painter G. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral. Res. 29:1996;53-56.
39. 14C-amprenavir in human volunteers. Pharm. Sci. 1:1998;S-150.
40. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J., Roden D.M., Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:1998;289-294.
41. Lee C.G., Gottesman M.M., Cardarelli C.O., Ramachandra M., Jeang K.-T., Ambudkar S.V., Pastan I., Dey S. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry. 37:1998;3594-3601.
42. Hellriegel E.T., Bjornsson T.D., Hauck W.W. Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin. Pharmacol. Ther. 60:1996;601-607.
43. Vella S., Floridia M. Saquinavir. Clinical pharmacology and efficacy. Clin. Pharmacokinet. 34:1998;189-201.
44. Muirhead G.J., Shaw T., Williams P.E., Madigan M.J., Mitchell A.M., Houston A.C. Pharmacokinetics of the HIV-proteinase inhibitor, Ro 318959, after single and multiple oral doses in healthy volunteers. Br. J. Clin. Pharmacol. 34:1992;170P-171P.
45. Hsu A., Granneman R., Rynkiewicz K., Valdes J., Mayer K., Leonard J. Kinetics of ABT-538, a protease inhibitor, in humans after single oral rising doses. Pharm. Res. 11:1994;S-400.
46. Moyle G.J., Youle M., Higgs C., Monaghan J., Prince W., Chapman S., Clendeninn N., Nelson M.R. Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus. J. Clin. Pharmacol. 38:1998;736-743.
47. Perry C.M., Benfield P. Nelfinavir. Drugs. 54:1997;81-87.
48. Lea A.P., Faulds D. Ritonavir. Drugs. 52:1996;541-546.
49. Decker C.J., Laitinen L.M., Bridson G.W., Raybuck S.A., Tung R.D., Chaturvedi P.R. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J. Pharm. Sci. 87:1998;803-807.
50. Adkins J.C., Faulds D. Amprenavir. Drugs. 55:1998;837-842.
51. Kenyon C.J., Brown F., McClelland G.R., Wilding I.R. The use of pharmacoscintigraphy to elucidate food effects observed with a novel protease inhibitor (saquinavir). Pharm. Res. 15:1998;417-422.
52. Groothuis D.R., Levy R.M. The entry of antiviral and antiretroviral drugs into the central nervous system. J. Neurovirol. 3:1997;387-400.
53. Brinkman K., Kroon F., Hugen P.W., Burger D.M. Therapeutic concentrations of indinavir in cerebrospinal fluid of HIV-1-infected patients. AIDS. 12:1998;537.
54. Stahle L., Martin C., Svensson J.-O., Sonnerborg A. Indinavir in cerebrospinal fluid of HIV-1-infected patients. Lancet. 350:1997;1823.
55. Lin J.H., Chiba M., Balani S.K., Chen I.-W., Kwei G.Y., Vastag K.J., Nishime J.A. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 24:1996;1111-1120.
56. Denissen J.F., Grabowski B.A., Johnson M.K., Buko A.M., Kempf D.J., Thomas S.B., Surber B.W. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab. Dispos. 25:1997;489-501.
57. Shetty B.V., Kosa M.B., Khalil D.A., Webber S. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 40:1996;110-114.
58. Aungst B.J. Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J. Pharm. Sci. 82:1993;979-987.
59. Thummel K.E., Kunze K.L., Shen D.D. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv. Drug Del. Rev. 27:1997;99-127.
60. Hebert M.F. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv. Drug Del. Rev. 27:1997;201-214.
61. Benet L.Z., Wu C.-Y., Hebert M.F., Wacher V.J. Intestinal drug metabolism and antitransport processes: a potential paradigm shift in oral drug delivery. J. Control. Release. 39:1996;139-143.
62. Wacher V.J., Wu C.-Y., Benet L.Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinogen. 13:1995;129-134.
63. Rendic S., Di Carlo F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab. Rev. 29:1997;413-580.
64. Wrighton S.A., Ring B.J., Watkins P.B., VandenBranden M. Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol. Pharmacol. 36:1989;97-105.
65. Watkins P.B., Wrighton S.A., Schuetz E.G., Molowa D.T., Guzelian P.S. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J. Clin. Invest. 80:1987;1029-1036.
66. Watkins P.B. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Del. Rev. 27:1997;161-170.
67. Kolars J.C., Schmiedlin-Ren P., Schuetz J.D., Fang C., Watkins P.B. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 90:1992;1871-1878.
68. Lown K.S., Kolars J.C., Thummel K.E., Barnett J.L., Kunze K.L., Wrighton S.A., Watkins P.B. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test [Erratum: (1995) Drug Metab. Dispos. 23]. Drug Metab. Dispos. 22:1994;947-955.
69. Fitzsimmons M.E., Collins J.M. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4. Potential contribution to high first-pass metabolism. Drug Metab. Dispos. 25:1997;256-266.
70. Thummel K.E., O'Shea D., Paine M.F., Shen D.D., Kunze K.L., Perkins J.D., Wilkinson G.R. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59:1996;491-502.
71. Paine M.F., Shen D.D., Kunze K.L., Perkins J.D., Marsh C.L., McVicar J.P., Barr D.M., Gillies B.S., Thummel K.E. First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther. 60:1996;14-24.
72. Eagling V.A., Back D.J., Barry M.G. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br. J. Clin. Pharmacol. 44:1997;190-194.
73. von Moltke L.L., Greenblatt D.J., Grassi J.M., Granda B.W., Duan S.X., Fogelman S.M., Daily J.P., Harmatz J.S., Shader R.I. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J. Clin. Pharmacol. 38:1998;106-111.
74. ®. American Society of Health-System Pharmacists, Bethesda, MD, 1998, pp. 562-572.
75. Kumar G.N., Rodrigues A.D., Buko A.M., Denissen J.F. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes [published erratum appears in J. Pharmacol. Exp. Ther. (1997) 281, 1506]. J. Pharmacol. Exp. Ther. 277:1996;423-431.
76. Koudriakova T., Iatsimirskaia E., Utkin I., Gangl E., Vouros P., Storozhuk E., Orza D., Marinina J., Gerber N. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab. Dispos. 26:1998;552-561.
77. Chiba M., Hensleigh M., Nishime J.A., Balani S.K., Lin J.H. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 24:1996;307-314.
78. Balani S.K., Arison B.H., Mathai L., Kauffman L.R., Mille R.R., Stearns R.A., Chen I.-W., Lin J.H. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab. Dispos. 23:1995;266-270.
79. Chiba M., Hensleigh M., Lin J.H. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A. Biochem. Pharmacol. 53:1997;1187-1195.
80. Balani S.K., Woolf E.J., Hoagland V.L., Sturgill M.G., Deutsch P.J., Yeh K.C., Lin J.H. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab. Dispos. 24:1996;1389-1394.
81. Kerr B., Lee C., Yuen G., et al. Overview of in vitro and in vivo, drug interaction studies of nelfinavir, a new HIV-1 protease inhibitor. 4th Conference On Retroviruses and Opportunistic Infections. 1997.
82. Jarvis B., Faulds D. Nelfinavir. A review of its therapeutic efficacy in HIV infection. Drugs. 56:1998;147-167.
83. Lee C.A., Liang B.-H., Wu E.Y., Grettenberger H.M., Sandoval T.M., Zhang K.E., Shetty B.V. Prediction of nelfinavir mesylate (Viracept) clinical drug interactions based on in vitro human P450 metabolism studies. 4th Conference On Retroviruses and Opportunistic Infections. 1997;A523.
84. Lillibridge J.H., Liang B.H., Kerr B.M., Webber S., Quart B., Shetty B.V., Lee C.A. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab. Dispos. 26:1998;609-616.
85. Woolley J., Studenberg S., Boehlert C., Bowers G., Sinahababu A., Adams P. Cytochrome P-450 isozyme induction, inhibition, and metabolism studies with the HIV protease inhibitor, 141W94. Proceedings of the Interscience Conference On Antimicrobial Agents and Chemotherapy September. 1997;A-60.
86. Li A.P., Jurima-Romet M. Overview: pharmacokinetic drug-drug interactions. Adv. Pharmacol. 43:1997;1-6.
87. Ford J.M., Hait W.N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42:1990;155-199.
88. Kusuhara H., Suzuki H., Sugiyama Y. The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. J. Pharm. Sci. 87:1998;1025-1040.
89. Makhey V.D., Guo A., Norris D.A., Hu P., Yan J., Sinko P.J. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm. Res. 15:1998;1160-1167.
90. Kiuchi Y., Suzuki H., Hirohashi T., Tyson C.A., Sugiyama Y. cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). FEBS Lett. 433:1998;149-152.
91. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA. 84:1987;7735-7738.
92. Prueksaritanont T., Deluna P., Gorham L.M., Ma B., Cohn D., Pang J., Xu X., Leung K., Lin J.H. In vitro and in vivo evaluations of intestinal barriers for the zwitterion L-767,679 and its carboxyl ester prodrug L-775,318. Roles of efflux and metabolism. Drug Metab. Dispos. 26:1998;520-527.
93. Floren L.C., Bekersky I., Benet L.Z., Mekki Q., Dressler D., Lee J.W., Roberts J.P., Hebert M.F. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin. Pharmacol. Ther. 62:1997;41-49.
94. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.A., van der Valk M.A., Robanus-Maandag E.C., te Riele H.P., Berns A.J., Borst P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 77:1994;491-502.
95. Schinkel A.H., Wagenaar E., Mol C.A., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97:1996;2517-2524.
96. Hunter J., Jepson M.A., Tsuruo T., Simmons N.L., Hirst B.H. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J. Biol. Chem. 268:1993;14991-14997.
97. Hunter J., Hirst B.H., Simmons N.L. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm. Res. 10:1993;743-749.
98. Washington C.B., Duran G.E., Sikic B.I., Blaschke T.F. Saquinavir is a high affinity substrate for the multidrug transporter, P-glycoprotein. Clin. Pharmacol. Ther. 61:1997;193.
99. Mayer U., Wagenaar E., Dorobek B., Beijnen J.H., Borst P., Schinkel A.H. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin. Invest. 100:1997;2430-2436.
100. Dintaman J.M., Kim A.E., Waddell D.S., Silverman J.A. Saquinavir is a substrate for the multidrug resistance transporter P-glycoprotein. AAPS Western Regional Meeting, San Francisco, CA, USA. 1998;. Abstract #22.
101. Kim A.E., Dintaman J.M., Waddell D.S., Silverman J.A. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J. Pharmacol. Exp. Ther. 286:1998;1439-1445.
102. Makhey V.D., Sinko P.J. Investigation of stability, cytochrome P450-mediated metabolism and MDR-mediated efflux of the HIV protease inhibitor, saquinavir in humans and rats. Pharm. Res. 14:1997;S525-S526.
103. Kunta J.R., Williams G.C., Sinko P.J. Investigation of regional intestinal efflux of an HIV protease inhibitor, saquinavir, in rat jejunum. Pharm. Sci. 1:1998;S457.
104. Williams G.C., Kunta J.R., Sinko P.J. Characterization of the secretory efflux of ritonavir, an HIV protease inhibitor, using rat jejunum. Pharm. Sci. 1:1998;S12.
105. Hidalgo I.J., Borchardt R.T. Transport of a large neutral amino acid (phenylalanine) in a human intestinal epithelial cell line: Caco-2. Biochim. Biophys. Acta. 1028:1990;25-30.
106. Glynn S.L., Yazdanian M. In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J. Pharm. Sci. 87:1998;306-310.
107. Polli J.W., Studenberg S., Jarrett J.L., Serabjit-Singh C., Humphreys J.E., Brouwer K.R., Woolley J.L. Effect of P-glycoprotein on the CNS disposition of amprenavir and HIV protease inhibitors. Pharm. Sci. 1:1998;S396.
108. Hyafil F., Vergely C., Du Vignaud P., Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53:1993;4595-4602.
109. Lown K.S., Mayo R.R., Leichtman A.B., Hsiao H.-L., Turgeon D.K., Schmiedlin-Ren P., Brown M.B., Guo W., Rossi S.J., Benet L.Z., Watkins P.B. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62:1997;248-260.
110. Gan L.-S., Moseley M.A., Khosla B., Augustijns P.F., Bradshaw T.P., Hendren R.W., Thakker D.R. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Interaction between the two biochemical barriers to intestinal transport. Drug Metab. Dispos. 24:1996;344-349.
111. Fischer V., Rodriguez-Gascon A., Heitz F., Tynes R., Hauck C., Cohen D., Vickers A.E. The multidrug resistance modulator Valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab. Dispos. 26:1998;802-811.
112. Schuetz E.G., Beck W.T., Schuetz J.D. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 49:1996;311-318.
113. O'Brien L.W. Clinical rounds. Interactions and toxicities of drugs for HIV disease. Drug Benefit Trends. 1998;44-52. July.
114. Bretzel R., Boeth J. Polypharmacy and the treatment of HIV/AIDS. By understanding adverse effects and drug interactions, pharmacists can improve compliance and quality of life for their patients with AIDS. J. Am. Pharm. Assoc. NS36:1996;722a-722e.
115. Barry M., Gibbons S., Back D., Mulcahy F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin. Pharmacokinet. 32:1997;194-209.
116. Sparano J.A., Wiernik P.H., Hu X., Sarta C., Henry D.H., Ratech H. Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma. Med. Oncol. 15:1998;50-57.
117. Kumar G.N., Grabowski B., Lee R., Denissen J.F. Hepatic drug-metabolizing activities in rats after 14 days of oral administration of the human immunodeficiency virus-type 1 protease inhibitor ritonavir (ABT-538). Drug Metab. Dispos. 24:1996;615-617.
118. Webber S., Shetty B., Wu E., Zorbas M. In vitro and in vivo metabolism and cytochrome P450 induction studies with the HIV-1 protease inhibitor, Viracept (AG1343). 3rd Conference On Retroviruses and Opportunistic Infections. 1996;79.
119. Kempf D.J., Marsh K.C., Kumar G., Rodrigues A.D., Denissen J.F., McDonald E., Kukulka M.J., Hsu A., Granneman G.R., Baroldi P.A., Sun E., Pizzuti D., Plattner J.J., Norbeck D.W., Leonard J.M. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:1997;654-660.